## **AMENDMENTS TO THE CLAIMS**

Claims 1-18. (cancelled)

Claim 19. (new) A compound of formula (I)

$$R^{5} \xrightarrow{Y} A - Q \xrightarrow{(CH_{2})_{n}} N \xrightarrow{R^{2}} R^{1}$$

$$\downarrow O \\ (CH_{2})_{m} N \xrightarrow{X} O$$

$$\downarrow O \\ (CH_{2})_{m} N \xrightarrow{X} O$$

$$\downarrow O \\ OH$$

$$\downarrow O \\ OH$$

wherein

A is an alkylene group, an alkenylene group, an alkynylene group, a heteroalkylene group, a cycloalkylene group, a heterocycloalkylene group, an arylene group or a heteroarylene group all of which groups may be substituted;

Q is CR<sup>4</sup> or N;

X is CR<sup>7</sup> or N;

Y is CR<sup>6</sup> or N;

n is 1, 2 or 3;

m is 1, 2 or 3;

R<sup>1</sup> is H, F, Cl, Br, I, OH, NH<sub>2</sub>, an alkyl group or a heteroalkyl group;

R<sup>2</sup> is H, F or Cl;

R<sup>3</sup> is H, an alkyl group, an alkenyl group, an alkynyl group, a heteroalkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an alkylaryl group or a heteroarylalkyl group; all of which groups may be substituted with one, two or more halogen atoms or amino groups;

R<sup>4</sup> is hydroxy, a group of formula OPO<sub>3</sub>R<sup>9</sup><sub>2</sub> or OSO<sub>3</sub>R<sup>10</sup> or a heteroalkyl group carrying at least one OH, NH<sub>2</sub>, SO<sub>3</sub>R<sup>10</sup>, PO<sub>3</sub>R<sup>9</sup><sub>2</sub> or COOH group or an ester of a naturally occurring amino acid or a derivative thereof, wherein the groups R<sup>9</sup> independently of each other are H, alkyl, cycloalkyl, aryl or aralkyl and wherein R<sup>10</sup> is H, alkyl, cycloalkyl, aryl or aralkyl;

R<sup>5</sup> is selected from the following groups:

R<sup>6</sup> is H, F, Cl or OMe;

R<sup>7</sup> is H, F, Cl, OH, NH<sub>2</sub>, a substituted or unsubstituted alkyl group or a substituted or unsubstituted heteroalkyl group, or

R<sup>3</sup> and R<sup>7</sup> can be linked via an alkylene, an alkenylene or a heteroalkylene group or be a part of a cycloalkylene or heterocycloalkylene group; in case R<sup>3</sup> is no H and R<sup>7</sup> is no H, F, OH, NH<sub>2</sub> or CI; and

 $R^8$  is a  $C_{1-6}$  heteroalkyl, a heteroarylalkyl, a heteroalkylaryl or a heteroalkylheteroaryl group;

Application No. National Phase of PCT/EP04/014500 Amendment dated June 14, 2006 First Preliminary Amendment Page 4

or a pharmacologically acceptable salt, solvate, hydrate or formulation thereof.

- Claim 20. (new) A compound of claim 19, wherein R<sup>1</sup> is H.
- Claim 21. (new) A compound according to claim 19, wherein R<sup>2</sup> is F or H.
- Claim 22. (new) A compound of claim 19, wherein  $R^3$  is an ethyl, a 2-propyl, a  $C_3$ - $C_6$  cycloalkyl, a phenyl or a pyridyl group; all of which may be substituted with one, two, three or more fluorine atoms or amino groups.
- Claim 23. (new) A compound according to claim 19, wherein R<sup>3</sup> is a cyclopropyl group.
- Claim 24. (new) A compound of claim 19, wherein R<sup>7</sup> and R<sup>3</sup> together form a bridge of the formula –O-CH<sub>2</sub>-N(Me)- or -O-CH<sub>2</sub>-CH(Me)-, wherein the preferred stereochemistry at the chiral center is the one giving the (S) configuration in the final compound.
- Claim 25. (new) A compound of claim 19, wherein R<sup>7</sup> is H, F, Cl or a methoxy group which may be substituted by one, two or three fluorine atoms.
  - Claim 26. (new) A compound of claim 19, wherein X is N or CH.
- Claim 27. (new) A compound of claim 19, wherein R<sup>4</sup> is hydroxy or a group of formula OSO<sub>3</sub>H, OPO<sub>3</sub>H<sub>2</sub>, OCH<sub>2</sub>OPO<sub>3</sub>H<sub>2</sub>, OCOCH<sub>2</sub>CH<sub>2</sub>COOH or an ester of a naturally occurring amino acid or a derivative thereof.
- Claim 28. A compound of claim 19, wherein R<sup>8</sup> is a group of the formula -CH<sub>2</sub>NHCOCH=CHAryl, -CH<sub>2</sub>OHeteroaryl, -CH<sub>2</sub>NHSO<sub>2</sub>Me, -CH<sub>2</sub>NHCOMe, -CH<sub>2</sub>NHCSOMe, -CH<sub>2</sub>NHCSOMe, -CH<sub>2</sub>NHCSOMe, -CH<sub>2</sub>NHCSOMe or -NHCOMe.

Application No. National Phase of PCT/EP04/014500 Amendment dated June 14, 2006 First Preliminary Amendment Page 5

Claim 29. (new) A compound of claim 19, wherein R<sup>5</sup> has the following structure:

Claim 30. (new) A compound of claim 19, wherein Y is CH or N.

Claim 31. (new) A compound of claim 19, wherein A is  $C_{1-6}$  alkylene,  $C_{2-6}$  alkenylene,  $C_{2-6}$  alkynylene,  $C_{1-6}$  heteroalkylene, cyclopropylene, epoxide, aziridine, thioepoxide, lactame or lactone, all of which groups may be substituted.

Claim 32. (new) A compound of claim 19, wherein A is a group of formula  $-CH_2CH_2-$ ,  $-OCH_2-$ ,  $-OCH_2CH_2-$ ,  $-SCH_2-$ ,  $-SCH_2CH_2-$ , -CH=CH-,  $-C\equiv C-$ , -CH(OH)CH(OH)- or  $-CH(NH_2)CH(OH)-$ .

Claim 33. (new) A mono, di or tri sodium salt of a compound of formula (l) according to claim 19.

Claim 34. (new) A compound of claim 33 wherein R<sup>4</sup> is OPO<sub>3</sub>H<sub>2</sub> or OSO<sub>3</sub>H or mixtures thereof.

Claim 35. (new) A pharmaceutical composition comprising a compound of claim 19.

Claim 36. (new) The pharmaceutical composition of claim 35 further comprising one or more optionally carriers and/or adjuvants and/or diluents.

Application No. National Phase of PCT/EP04/014500 Amendment dated June 14, 2006 First Preliminary Amendment Page 6

\* \*\*

Claim 37. (new) A pro-drug comprising a compound of claim 19 and at least one pharmacologically acceptable protective group.

Claim 38. (new) A method for treating a subject suffering from or susceptible to a bacterial infection, comprising administering to the subject a compound of claim 19.